|
|
 Previous Article | Table of Contents | Next Article 
Eradication of minimal disease in severe combined immunodeficient mice with
disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail
MA Ghetie, K Tucker, J Richardson, JW Uhr and ES Vitetta
Cancer Immunobiology Center, University of Texas Southwestern Medical
Center at Dallas.
Severe combined immunodeficient (SCID) mice injected intravenously with a
human Burkitt's lymphoma cell line (Daudi) develop disseminated lymphoma
(SCID/Daudi), which is fatal in 100% of the mice. Early treatment of these
mice with either an immunotoxin (IT) cocktail (consisting of
anti-CD19-ricin A chain plus anti-CD22-ricin A chain) or chemotherapy
significantly prolonged survival but was not curative. Combination therapy
with the IT cocktail and any one of three chemotherapeutic drugs
(doxorubicin, cytoxan, or camptothecin) cured the mice. Cure was
demonstrated by both histopathologic examination of treated mice and, more
importantly, by adoptive transfer of cells from organs of the cured mice to
naive SCID mice where 100 tumor cells would have caused disease in the
recipients. These results provide a strong rationale for combining IT
therapy with conventional chemotherapy in the treatment of B-cell
neoplasia.
Volume 84,
Issue 3,
pp. 702-707,
08/01/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D A Vallera, B J Stish, Y Shu, H Chen, A Saluja, D J Buchsbaum, and S M Vickers
Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model
Gut,
May 1, 2008;
57(5):
634 - 641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Vallera, D. A. Todhunter, D. W. Kuroki, Y. Shu, A. Sicheneder, and H. Chen
A Bispecific Recombinant Immunotoxin, DT2219, Targeting Human CD19 and CD22 Receptors in a Mouse Xenograft Model of B-Cell Leukemia/Lymphoma
Clin. Cancer Res.,
May 15, 2005;
11(10):
3879 - 3888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saudemont and B. Quesnel
In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis
Blood,
October 1, 2004;
104(7):
2124 - 2133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Sapra and T. M. Allen
Improved Outcome When B-Cell Lymphoma Is Treated with Combinations of Immunoliposomal Anticancer Drugs Targeted to Both the CD19 and CD20 Epitopes
Clin. Cancer Res.,
April 1, 2004;
10(7):
2530 - 2537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Newton, H. J. Hansen, S. M. Mikulski, D. M. Goldenberg, and S. M. Rybak
Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma
Blood,
January 15, 2001;
97(2):
528 - 535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B.-R. Wei, M.-A. Ghetie, and E. S. Vitetta
The Combined Use of an Immunotoxin and a Radioimmunoconjugate to Treat Disseminated Human B-Cell Lymphoma in Immunodeficient Mice
Clin. Cancer Res.,
February 1, 2000;
6(2):
631 - 642.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. Breistol, J. Balzarini, M. L. Sandvold, F. Myhren, M. Martinsen, E. D. Clercq, and O. Fodstad
Antitumor Activity of P-4055 (Elaidic Acid-Cytarabine) Compared to Cytarabine in Metastatic and s.c. Human Tumor Xenograft Models
Cancer Res.,
June 1, 1999;
59(12):
2944 - 2949.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
